Markets › United States › NAS › HALO

Halozyme Therapeutics Inc

NAS:HALOHealthcareNASDAQ:NBINASDAQ:NQUSMG

$122.50+0.54%At closeAt close · Tue 20 Oct · ≈ AED 449.88 · Market cap $13.9B · Next earnings Mon 2 Nov

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	83.8%	81.6%	78.9%	76.8%	84.3%	78.1%	—	—
Operating margin	53.9%	62.2%	40.5%	40.7%	54.3%	58.4%	58.4%	+0.0 pts
Net margin	48.2%	90.8%	30.6%	34.0%	43.7%	22.7%	22.7%	+0.0 pts
EBITDA margin	57.2%	58.4%	47.8%	54.5%	64.7%	41.0%	—	—
Return on equity	85.5%	204.5%	119.0%	336.0%	122.1%	649.2%	649.2%	+0.0 pts
Return on assets	22.3%	36.5%	11.0%	16.2%	21.5%	12.5%	12.5%	+0.0 pts
Return on capital employed	91.0%	27.9%	15.6%	20.8%	28.7%	34.8%	—	—
Debt / equity	2.6×	4.5×	8.9×	17.9×	4.1×	43.9×	43.9×	+0.0%
Debt / assets	68.5%	79.4%	81.8%	86.5%	73.0%	84.8%	—	—
Interest coverage	7.1×	36.7×	15.8×	18.0×	30.5×	45.0×	—	—
Current ratio	1.3×	7.9×	5.7×	6.6×	7.8×	4.7×	4.7×	+0.0%
Quick ratio	1.2×	7.4×	4.9×	5.5×	6.8×	3.7×	—	—
Cash ratio	0.4×	1.0×	1.8×	1.1×	0.8×	0.8×	0.8×	+0.0%
Asset turnover	0.5×	0.4×	0.4×	0.5×	0.5×	0.6×	—	—
Inventory turnover	0.7×	1.5×	1.4×	1.5×	1.1×	1.7×	—	—
Receivables turnover	2.7×	4.9×	2.9×	3.5×	3.3×	3.2×	—	—
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—	—